Physician profile
Hyewon Jung
NPI 1477940542
$893.78
in general payments reported to CMS, 2019-2025
12 companies · $343 in 2025
The $343 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $284 · 2024: $266 · 2025: $343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $609.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $609.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $439.27 | 2021-2025 | Enhertu, Calquence, Lynparza |
| Seagen INC. | $141.98 | 2021 | |
| Genentech USA, INC. | $49.43 | 2024 | Tecentriq, Phesgo |
| Alexion Pharmaceuticals, INC. | $45.98 | 2024-2025 | Ultomiris |
| Merck Sharp & Dohme LLC | $43.14 | 2024-2025 | Keytruda, Lynparza |
| Astellas Pharma US INC | $33.59 | 2025 | Vyloy |
| Glaxosmithkline, LLC. | $28.75 | 2025 | Jemperli, Zejula |
| Genmab U.S., INC. | $27.04 | 2025 | Tivdak |
| Geron Corporation | $26.16 | 2025 | Rytelo |
| Grifols USA, LLC | $21.29 | 2024 | Gamunex-C |
| Tersera Therapeutics LLC | $20.35 | 2025 | Zoladex |
| Incyte Corporation | $16.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hyewon Jung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.